Last year, Sarepta Therapeutics Inc generated 965.57M USD for its biggest-performing segment, PMO Products. The United States made the largest contribution, accounting for 1.70B USD last year. For the latest quarter, Sarepta Therapeutics Inc reported the revenue of 230.56M USD for the period ending 2026-06-30, which came from the top-performing segment, PMO Products. United States contributed the highest revenue, at 296.73M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

PMO Products

ELEVIDYS

collaboration and other

FY2025

FY2024

FY2023

PMO Products

965.57M(43.92%)

967.17M(50.85%)

944.52M(75.97%)

ELEVIDYS

898.73M(40.88%)

820.79M(43.15%)

200.36M(16.11%)

collaboration and other

333.94M(15.19%)

114.02M(5.99%)

98.46M(7.92%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

Rest of World

FY2025

FY2024

FY2023

United States

1.70B(91.14%)

1.64B(91.60%)

998.30M(87.20%)

Rest of World

165.18M(8.86%)

150.25M(8.40%)

146.58M(12.80%)